Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $147.3 million.

  • Caribou Biosciences' Cash & Current Investments fell 3546.31% to $147.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.3 million, marking a year-over-year decrease of 3546.31%. This contributed to the annual value of $209.5 million for FY2024, which is 3627.74% down from last year.
  • Latest data reveals that Caribou Biosciences reported Cash & Current Investments of $147.3 million as of Q3 2025, which was down 3546.31% from $183.9 million recorded in Q2 2025.
  • Caribou Biosciences' Cash & Current Investments' 5-year high stood at $435.3 million during Q3 2021, with a 5-year trough of $129.5 million in Q2 2021.
  • Over the past 5 years, Caribou Biosciences' median Cash & Current Investments value was $259.2 million (recorded in 2023), while the average stood at $263.7 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 225587.04% in 2021, then plummeted by 3627.74% in 2024.
  • Caribou Biosciences' Cash & Current Investments (Quarter) stood at $375.8 million in 2021, then crashed by 34.1% to $247.7 million in 2022, then soared by 32.77% to $328.8 million in 2023, then tumbled by 36.28% to $209.5 million in 2024, then fell by 29.72% to $147.3 million in 2025.
  • Its last three reported values are $147.3 million in Q3 2025, $183.9 million for Q2 2025, and $208.5 million during Q1 2025.